Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNAseq of Cyp11a1-expressing cells from mouse melanoma model derived tumors

ABSTRACT: scRNAseq of Cyp11a1-expressing cells from mouse melanoma model derived tumors

PROVIDER: PRJEB35363 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3658100_1.fastq.gz	Fastqsanger.gz
	ERR3658100_2.fastq.gz	Fastqsanger.gz
	ERR3658110_1.fastq.gz	Fastqsanger.gz
	ERR3658110_2.fastq.gz	Fastqsanger.gz
	ERR3658120_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6910

Similar Datasets

scRNAseq of Cyp11a1-expressing cells from mouse melanoma model derived tumors

Project description:Tumours induce de novo steroidogenesis in immune cells. We wanted to define the gene expression identity of intratumoural steroidogenic immune cells and compare them with the transcriptome with non-steroidogenic cells. Cyp11a1 expression is a faithful biomarker of de novo steroidogenesis (i.e. Cyp11a1+ cells are steroidogenic and Cyp11a1- cells are non-steroidogenic). We inoculated B16-F10 tumor in Cyp11a1-mCherry reporter mice, enriched and purified intratumoral Cyp11a1-mCherry+ and Cyp11a1-mCherry- cells by cell sorting into 96-well plates [with a ratio of 79:15 (mCherry+ : mCherry-) cells per plate] and performed scRNA-seq using SMART-Seq2 platform.

2020-05-27 | E-MTAB-8509 | biostudies-arrayexpress

Melanoma GEMM Tumors, untreated or vemurafenib treated (scRNASeq)

Project description:Melanoma GEMM Tumors, untreated or vemurafenib treated (scRNASeq)

| PRJNA523031 | ENA

e18.5 pancreas: WT vs Cyp11a1 KO

Project description:RNA profiling of WT and cyp11a1 KO pancreas at e18.5

2021-06-25 | GSE178633 | GEO

Melanoma GEMM Tumors, untreated or vemurafenib treated (scRNASeq)

Project description:Emerging research suggests that multiple tumor compartments can influence treatment responsiveness and relapse, yet the search for therapeutic resistance mechanisms remains largely focused on acquired genomic alterations in cancer cells. Here, we show how treatment-induced changes occur in multiple tumor compartments during tumor relapse and can reduce benefit of follow-on therapies. By utilizing serial biopsies, next generation sequencing and single cell transcriptomics, we tracked the evolution of multiple cellular compartments within individual lesions during first-line treatment response, relapse and second-line therapeutic interventions in an autochthonous model of melanoma. We discovered that while treatment-relapsed tumors remained genetically stable, they converged on a shared resistance phenotype characterized by dramatic changes in tumor cell differentiation state, immune infiltration and extracellular matrix (ECM) composition. Similar alterations in tumor cell differentiation were also observed in more than half of our treatment-relapsed patient tumors. Tumor cell state changes were coincident with ECM remodeling and increased tumor stiffness, which alone was sufficient to alter tumor cell fate and reduce treatment responses in melanoma cell lines in vitro. Despite the absence of acquired mutations in the targeted pathway, resistant tumors showed significantly decreased responsiveness to second-line therapy intervention within the same pathway. The ability to preclinically model relapse and refractory settings - while capturing dynamics within and crosstalk between all relevant tumor compartments - provides a unique opportunity to better design and sequence appropriate clinical interventions. The "SAMPLE_ID" sample characteristic is a sample identifier internal to Genentech. The ID of this project in Genentech's ExpressionPlot database is NGS2034.

2019-03-08 | GSE126714 | GEO

The Role of DNMT1 and C/EBPα in the Regulation of CYP11A1 Expression During Syncytialization of Human Placental Trophoblasts

Project description:Progesterone synthesized in the placenta is essential for pregnancy maintenance. CYP11A1 is a key enzyme in progesterone synthesis, and its expression increases greatly during trophoblast syncytialization. However, the underlying mechanism remains elusive. Here, we demonstrated that passive demethylation of CYP11A1 promoter accounted for the upregulation of CYP11A1 expression during syncytialization with the participation of the transcription factor C/EBPα. We found that the methylation rate of a CpG locus in the CYP11A1 promoter was significantly reduced along with decreased DNA methyltransferase 1 (DNMT1) expression and its enrichment at the CYP11A1 promoter during syncytialization. DNMT1 overexpression not only increased the methylation of this CpG locus in the CYP11A1 promoter, but also decreased CYP11A1 expression and progesterone production. In silico analysis disclosed multiple C/EBPα binding sites in both CYP11A1 and DNMT1 promoters. C/EBPα expression and its enrichments at both the DNMT1 and CYP11A1 promoters were significantly increased during syncytialization. Knocking-down C/EBPα expression increased DNMT1 while it decreased CYP11A1 expression during syncytialization. Conclusively, C/EBPα plays a dual role in the regulation of CYP11A1 during syncytialization. C/EBPα not only drives CYP11A1 expression directly, but also indirectly through downregulation of DNMT1, which leads to decreased methylation in the CpG locus of the CYP11A1 promoter, resulting in increased progesterone production during syncytialization.

2024-08-05 | GSE183700 | GEO

scRNAseq of NT2.5 and NT2.5-LM breast tumors

Project description:Syngeneic NT2.5 and NT2.5-LM breast tumors established in female NeuN mice were collected and sent for scRNAseq to examine various cell populations

2024-06-30 | GSE261252 | GEO

RNAseq and scRNAseq analysis of UPFL mouse tumors

Project description:RNAseq and scRNAseq analysis of UPFL mouse tumors

| PRJNA896928 | ENA

scRNAseq of NT2.5 and NT2.5-LM breast tumors

Project description:scRNAseq of NT2.5 and NT2.5-LM breast tumors

| PRJNA1086172 | ENA

scRNAseq of TAZ-CAMTA1 expressing endothelial cells in vivo

Project description:scRNAseq of TAZ-CAMTA1 expressing endothelial cells in vivo

| PRJNA659048 | ENA

Expression data from melanoma xenograft tumors originating from primary immortalized melanocytes

Project description:PREX2 truncating mutations occur in melanoma. We used microarray based gene expression profiling to compare expression patterns between xenografts harboring control GFP, wt PREX2 or various human relevant PREX2 mutants Primary xenograft tumors derived from primary immortalized melanocytes expressing indicated constructs were grown in ncr-nude mice and tumors harvested before before reaching 1.5cm size

2016-04-06 | E-GEOD-57309 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data